Bristol-Myers Squibb Is A Rare Dog Stock | $BMY Technical Analysis

TL;DR

Bristol Myers Squibb, a major drug company known for cancer research and drugs, is currently in a downtrend and considered a "dog stock."

Transcript

all right today we're gonna do bristol myers squib bristol myers is a nice drug company um they recently well 2019 acquired celgene corporation for 74 billion dollars so they're one of the bigger drug companies out there in the world i know they're in the top ten they do a lot of cancer research and come out with a lot of cancer drugs they have som... Read More

Key Insights

• 🥺 Bristol Myers Squibb is a leading drug company known for its cancer research and drugs.
• ℹ️ The acquisition of Celgene Corporation expanded the company's portfolio and revenue sources.
• 🤵 The stock is currently in a downtrend and considered a "dog stock."
• 🍉 Short-term trading may be complex due to various support and resistance levels.
• 🥳 Day trading could be a more suitable option for trading Bristol Myers Squibb.
• ❓ The company's size and potential executive issues may impact future performance.
• 🎚️ The stock is currently in a consolidation phase near support levels.

Questions & Answers

Q: What was the significance of Bristol Myers Squibb acquiring Celgene Corporation?

The acquisition made Bristol Myers Squibb one of the largest drug companies globally and added to its cancer research and drug portfolio.

Q: Why is Bristol Myers Squibb considered a "dog stock"?

The term "dog stock" refers to a stock that is in a downtrend and not showing much movement. Bristol Myers Squibb is currently in a consolidation phase near support levels.

Q: What factors should be considered when trading Bristol Myers Squibb in the short term?

Traders should be cautious due to the numerous support and resistance levels, making it a complicated stock to trade for swing trades. Day trading may be a better option due to the stock's range-bound and consolidating nature.

Q: What is the outlook for Bristol Myers Squibb in the long term?

From a long-term perspective, it may be worthwhile to buy one tracker share and wait for the red line on the stochastic indicator to move into the sweet spot for a positive direction. This allows for potential profits when the stock price increases.

Summary & Key Takeaways

• Bristol Myers Squibb acquired Celgene Corporation for $74 billion in 2019, making it one of the top ten drug companies globally, with a focus on cancer research and drugs.

• The company is collecting significant revenue from its drug Revlimid, which was a major driver for Celgene Corporation.

• While the acquisition was expected to lead to more growth, Bristol Myers Squibb is currently in a downtrend, with the stock price in a consolidation phase near support levels.